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SUMMARY
Fifty consecutive patients with erectile failure who had previously proved
refractory to papaverine and phentolamine intracavernosal therapy or were
inappropriate candidates forsuch treatment were treated with intracavernosal
prostaglandinE,. Fortypatients (80%) achievedanerectionsufficientforsexual
intercourse and aftera mean follow-up period of5.9 months, 32patients were
continuing to use treatmentsuccessfully. Theaveragedose was 14micrograms
(range 2.5 to 30 micrograms). There were no cases ofpriapism or cavernosal
fibrosis and no systemic side effects. A low incidence (8%) oflocal discomfort
was reported. Weconclude thatprostaglandin isasafeandeffective vasoactive
agent for the treatment oferectile failure in a genito-urinary outpatient clinic.
INTRODUCTION
The use ofintracavernous vasoactive agents has been shown to be effective in
the medical treatment of erectile dysfunction. Virag 'originally described the
use of the smooth muscle relaxant papaverine while Brindley 2 demonstrated
the effectiveness ofthe alpha adrenergic receptor blocker phenoxybenzamine.
A combination of papaverine plus phentolamine (an alpha-blocker) was
subsequently shown to be more effective than either agent alone3'4. Ishii 5 has
described the use ofprostaglandin-E1, and studies have since demonstrated its
efficacy in association with a reduced incidence of serious side effects6'7'8 We
are unaware of reports of the use of this drug in a genito-urinary clinic, and
describe our experience.
PATIENTS AND METHODS
Patients with erectile dysfunction were referred to the Genito-Clrinary Medicine
Clinic, which provides a weekly clinic for erectile dysfunction, from their
general practitioners or from consultant staff within the Northern Ireland
hospital system. After a detailed sexual and medical history a full physical
examinationwasperformedandbloodwastakenforhaemoglobinconcentration,
erythrocyte sedimentation rate, plasma glucose, liver function tests, testo-
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sterone and prolactin measurement. Intracavernous ProstaglandinEl was first
used in this clinic in November 1991, and this paper describes the first 50
patients. Those selected fulfilled one or more of the following criteria:
(1) Previous failure to achieve satisfactory erectile responseto papaverine 30
mg plus phentolamine 1 mg.
(2) Previouspriapismassociatedwithpapaverineplusphentolaminetreatment
or
(3) Patients with a history of serious ischaemic heart disease but who were
currently stable.
The latter group of patients were assessed by a consultant cardiologist to
ensure that treatment for their impotence was appropriate.
Intracavernous injection of 10 ,ug of prostaglandin was given with a fine bore
needle (26 gauge) into the lateral aspect of one of the corpora cavernosa at a
site 1-2 cms proximal to the coronal sulcus. It was not our routine practice to
use a constricting band atthe baseofthe penis atthe time ofinjection. The drug
was supplied in 1 ml ampoules containing 10 jg prostaglandin El. These were
individually prepared at the pharmacy of the Royal Victoria Hospital from
500,g ampoules (Upjohn). The initial dosage was 10 ,ug with appropriate
titration according to response up to a maximum of 30 ,ug. Once an erection
sufficient for sexual intercourse was achieved the patient was instructed in the
technique of self-injection and supervised to ensure that their technique was
correct. A supply ofneedles, syringes and prostaglandin El, was then provided
for home use with advice that the injection should not be used more than twice
perweek; the patient attended on a regular basis to monitor effectiveness, side
effects and to provide new supplies. Those who did not achieve an erection
sufficient for sexual intercourse despite maximal dosage of 30 jig were
assessed for a mechanical suction device.
RESULTS
Fifty patients satisfied the criteria for treatment between November 1991 and
September 1992. This represented approximately one third of patients on
intracavernosal treatment. Their average age was 52.5 years (range 25-74)
with a mean duration of impotence of 5.7 years (range 6 months - 30 years).
The aetiology was organic in 44 cases, psychogenic in 3 cases and uncertain
in three cases (Table 1). Five patients had had previous episodes of priapism.
TABLE 1
Aetiology ofimpotence
Aetiology Number ofpatients (%)
Vasculogenic 31 (62)
Diabetes 6 (12)
Neurgenic 5 (10)
Psychogenic 3 (6)
Idiopathic 3 (6)
Alcohol-related 2 (4)
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Forty patients (80%) achieved an erection sufficient for sexual intercourse; ten
failed. Inthosetreatedsuccessfullythe averagedosewas 14jg (range2.5-30),
theaveragedurationoferection being80 minutes (range20 minutes-4hours).
Oftheoriginal 40 patientswith a satisfactory response 32 arestill attending and
regularly using injection therapy after a mean follow-up period of 5.9 months
(range 1-11 months). Eight patients have failed to continue to attend for
unknown reasons.
Four patients complained of local pain in the penis, usually burning in nature
and associated with the erection. The aetiology oferectile failure in these cases
wasvasculogenic in two, diabetic in one andpsychogenic in one. Inthe diabetic
case local pain necessitated reduction ofthe dose from 10 to 5 jig. His erectile
,response was still satisfactory at the lower dose. To date there have been no
systemic side effects and no cases of priapism or corporeal fibrosis.
DISCUSSION
Prostaglandin El is an endogenous prostaglandin whose modeofaction has yet
to be fully elucidated. It acts as a powerful smooth muscle relaxant leading to
dilatation ofthe cavernosal arteries and relaxation ofthe cavernosal sinusoidal
smooth muscle. Itsefficacyhasbeenwelldocumented, with erections sufficient
for sexual intercourse reported in 68-86% of patients in unselected series5'9'10.
The response rate is highest in those ofpsychogenic and neurogenic origin, 7,8
reaching almost 100% in some series 7,8. A significantly lower rate of positive
response occurs in cases of vasculogenic or diabetic impotence . Our own
series was a selected group in terms of aetiology in that failure to respond to
papaverine plus phentolamine tended to favour patients with a vasculogenic
aetiology and this subgroup formed 60% of the total patient population. The
aetiological diagnosis was presumptive on the basis ofthe clinical history, the
presence ofcoexisting or previous significant medical conditions andthorough
physical examination. Angiography was not availableforfurther assessmentof
presumed vasculogenic cases and it is probable that there was some overlap
in the categories, most notably in diabetic cases where both vasculogenic and
neurogenic components are commonly present. The idiopathic group were
patients in whom no overt organic risk factor for erectile dysfunction could be
identified but who at the same time demonstrated no clear evidence of
psychological problems. Moreintensivepsychological andphysical assessment
might allow a more accurate classification of such patients. In this study the
overall response rateof80%demonstrates thesuperiorefficacyofprostaglandin
El inthetreatmentofvasculogenic impotence. Intheten caseswheretreatment
was unsuccessful the presumedaetiology wasvasculogenic inseven, idiopathic
in two and diabetic in one.
The use ofpapaverine has two principal complications, priapism andcorporeal
fibrosis. With the introduction of a combination of papaverine plus an alpha-
blocking agent the dosage of papaverine required to induce an erectile
response was significantly lowered, but despite this priapism and fibrosis
remain important clinical side effects. Ten percent of our patients were
commenced on prostaglandin El because ofprevious priapism associatedwith
papaverine and phentolamine treatment.
Prostaglandin El is a physiological agent partially metabolized locally within
the cavernous tissue, and approximately 70% eliminated in a single passage
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through the lungs 12. It is this rapid elimination which is believed to account for
the absence of systemic side effects even in the presence of venous leakage.
Many reports on its clinical use have shown a notable absence of priapism or
fibrosis 5,8, 9. Some authors,, however, have documented priapism requiring
treatment with metaraminol 10,' the most vulnerable group being those with a
non-vasculogenic aetiology. Cases of sustained erections of up to 11 hours
have also been described where spontaneous detumescence ultimately
occurred 6 1O. In our own series there were no cases of priapism or sustained
erection and this may be related to the selection of patients with vasculogenic
disease. Corporeal fibrosis and fibrotic thickening ofthe tunica albuginea have
been reported with papaverine injections and may be related to a number of
factors including repetitive needle trauma, organization of haematomas
associated with vascular puncture, or a local toxic reaction to papaverine
solution which is of low pH 1316. We found no cases of corporeal fibrosis
although the period of follow-up at present is relatively short.
In previous studies the most commonly described side effect of prostaglandin
El isthe occurrence oflocalized pain in the penis, varying in intensity from mild
discomfort to a severe burning sensation prohibiting sexual intercourse. The
reported incidence varies from 11% up to 75% 6-10, but was a complaint in only
four patients (8%) in our own series. In only one was a dose reduction required
to ameliorate this problem. Localized pain appears to occur more commonly
in those individuals whose impotence is non-vasculogenic in origin 10, which
may explain the low incidence of this series. Intracavernous prostaglandin E,
has proved an effective and safe alternative agent for the treatment of erectile
failure with particular application to those patients where treatment with
papaverine and phentolamine had been ineffective or inappropriate.
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